These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 37038911)

  • 1. Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors.
    Goetsch A; D'Amico F; Allocca M; Fiorino G; Furfaro F; Zilli A; Parigi TL; Radice S; Peyrin-Biroulet L; Danese S
    Expert Opin Pharmacother; 2023 May; 24(7):849-861. PubMed ID: 37038911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Filgotinib for moderately to severely active ulcerative colitis.
    Mannucci A; D'Amico F; El Saadi A; Peyrin-Biroulet L; Danese S
    Expert Rev Gastroenterol Hepatol; 2022 Oct; 16(10):927-940. PubMed ID: 36278878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Upadacitinib As a Second-line JAK Inhibitor in Ulcerative Colitis: A Case Series.
    Hosomi S; Nishida Y; Fujiwara Y
    Intern Med; 2024 Jul; 63(13):1882-1885. PubMed ID: 38008454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging therapies for ulcerative colitis.
    Hanzel J; Hulshoff MS; Grootjans J; D'Haens G
    Expert Rev Clin Immunol; 2022 May; 18(5):513-524. PubMed ID: 35477319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology and safety of tofacitinib in ulcerative colitis.
    López-Sanromán A; Esplugues JV; Domènech E
    Gastroenterol Hepatol; 2021 Jan; 44(1):39-48. PubMed ID: 32829958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK inhibitors: Novel developments in management of ulcerative colitis.
    Fiorino G; D'Amico F; Italia A; Gilardi D; Furfaro F; Danese S
    Best Pract Res Clin Gastroenterol; 2018; 32-33():89-93. PubMed ID: 30060943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study.
    Chen B; Zhong J; Li X; Pan F; Ding Y; Zhang Y; Chen H; Liu F; Zhang Z; Zhang L; Drozda R; Oliinyk O; Goh AH; Chen X; Sun X; Rubin DT; Sandborn WJ; Chen M
    Gastroenterology; 2022 Dec; 163(6):1555-1568. PubMed ID: 35963369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment.
    Nakase H
    Immunol Med; 2023 Sep; 46(3):121-130. PubMed ID: 37036140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of filgotinib in ulcerative colitis and Crohn's disease.
    Fanizza J; D'Amico F; Lauri G; Martinez-Dominguez SJ; Allocca M; Furfaro F; Zilli A; Fiorino G; Parigi TL; Radice S; Peyrin-Biroulet L; Danese S
    Immunotherapy; 2024 Feb; 16(2):59-74. PubMed ID: 38009327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of JAK inhibitors in Ulcerative Colitis.
    Ferrante M; Sabino J
    J Crohns Colitis; 2020 Aug; 14(Supplement_2):S737-S745. PubMed ID: 31879750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive overview of novel chemical drugs for ulcerative colitis: focusing on phase 3 and beyond.
    Neri B; Mancone R; Fiorillo M; Schiavone SC; De Cristofaro E; Migliozzi S; Biancone L
    Expert Opin Pharmacother; 2024 Apr; 25(5):485-499. PubMed ID: 38591242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis.
    D'Amico F; Magro F; Peyrin-Biroulet L; Danese S
    J Crohns Colitis; 2022 Jun; 16(5):835-844. PubMed ID: 34791103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of upadacitinib in the achievement of clinical and endoscopic remission in hospitalized patients with ulcerative colitis.
    Nakamura N; Honzawa Y; Ohtsu T; Sano Y; Ito Y; Fukata N; Fukui T; Naganuma M
    Clin J Gastroenterol; 2024 Aug; 17(4):654-657. PubMed ID: 38683411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials.
    D'Amico F; Fiorino G; Furfaro F; Allocca M; Danese S
    Expert Opin Investig Drugs; 2018 Jul; 27(7):595-599. PubMed ID: 29938545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
    Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis.
    Law CCY; Kayal M; Mehandru S; Colombel JF
    Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):109-117. PubMed ID: 36681073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology, efficacy and safety of JAK inhibitors in Crohn's disease.
    Ma C; Jairath V; Vande Casteele N
    Best Pract Res Clin Gastroenterol; 2019; 38-39():101606. PubMed ID: 31327403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.
    Núñez P; Quera R; Yarur AJ
    Drugs; 2023 Mar; 83(4):299-314. PubMed ID: 36913180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy.
    Napolitano M; D'Amico F; Ragaini E; Peyrin-Biroulet L; Danese S
    Drug Des Devel Ther; 2022; 16():1897-1913. PubMed ID: 35747444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolving role of JAK inhibitors in the treatment of inflammatory bowel disease.
    Gupta N; Papasotiriou S; Hanauer S
    Expert Rev Clin Immunol; 2023; 19(9):1075-1089. PubMed ID: 37226522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.